BioLineRx Ltd. Signs Exclusive License Agreement with Yissum Ltd. for Oral Phase II Ready Treatment BL-7040 for Inflammatory Bowel Disease

JERUSALEM--(BUSINESS WIRE)--BioLineRx (TASE:BLRX), a biopharmaceutical drug development company, and Yissum Research Development Company Ltd., the Technology Transfer Company of the Hebrew University of Jerusalem, announced today that they have signed a worldwide, exclusive license agreement for BioLineRx to develop and commercialize BL-7040, an orally available Phase II ready molecule for treating Inflammatory Bowel Disease (IBD) and other inflammatory diseases.